Bright Path Laboratories

Executive Summary

Bright Path Laboratories is addressing the critical U.S. dependence on foreign sources for active pharmaceutical ingredients (APIs) and key starting materials, which have led to high drug prices and supply chain vulnerabilities. By leveraging advanced manufacturing technologies, the company aims to reshore the production of essential generic drugs, ensuring a more resilient and affordable supply for American patients. Founded in 2016 and based in San Diego, Bright Path is focused on developing safe, sustainable, and cost-effective pharmaceutical manufacturing processes that reduce reliance on imports, particularly from countries that supply over 80% of U.S. key starting materials. The company's mission aligns with national priorities to strengthen domestic pharmaceutical infrastructure and mitigate the risks of supply disruptions, as highlighted by recent shortages of critical treatments. While still in the development stage, Bright Path represents a promising solution to a systemic problem, with the potential to transform the generic drug industry through localized production.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval of First Generic Drug Product40% success
• Q2 2026Strategic Partnership with a Major Pharmaceutical Company or Government Agency50% success
• Q3 2026Completion of Commercial-Scale Manufacturing Facility60% success